ECSP10010696A - Composiciones con y procedimientos para pirido[2,3-d]pirimidinas sustituidas con metilmorfolina - Google Patents
Composiciones con y procedimientos para pirido[2,3-d]pirimidinas sustituidas con metilmorfolinaInfo
- Publication number
- ECSP10010696A ECSP10010696A EC2010010696A ECSP10010696A ECSP10010696A EC SP10010696 A ECSP10010696 A EC SP10010696A EC 2010010696 A EC2010010696 A EC 2010010696A EC SP10010696 A ECSP10010696 A EC SP10010696A EC SP10010696 A ECSP10010696 A EC SP10010696A
- Authority
- EC
- Ecuador
- Prior art keywords
- pirido
- pyrimidins
- methylmorpholine
- procedures
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se estipula un proceso para la preparación de un compuesto de fórmula 1, el uso de dicho proceso en la preparación de un compuesto de fórmula 5 o de una de sus sales de fosfato, sulfato, sulfato ácido, malato, citrato, tartrato o fumarato, y el uso de la sal de fumarato en una composición para usar en terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7418808P | 2008-06-20 | 2008-06-20 | |
US15235009P | 2009-02-13 | 2009-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010696A true ECSP10010696A (es) | 2011-01-31 |
Family
ID=41051136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010696A ECSP10010696A (es) | 2008-06-20 | 2010-12-20 | Composiciones con y procedimientos para pirido[2,3-d]pirimidinas sustituidas con metilmorfolina |
Country Status (27)
Country | Link |
---|---|
US (1) | US8198441B2 (es) |
EP (1) | EP2303875B1 (es) |
JP (1) | JP5607614B2 (es) |
KR (1) | KR101668497B1 (es) |
CN (1) | CN102137860B (es) |
AR (1) | AR072263A1 (es) |
AU (1) | AU2009261688B2 (es) |
BR (1) | BRPI0914912A2 (es) |
CA (1) | CA2728183C (es) |
CL (1) | CL2010001488A1 (es) |
CO (1) | CO6351729A2 (es) |
CR (1) | CR11859A (es) |
DO (1) | DOP2010000391A (es) |
EA (1) | EA019092B1 (es) |
EC (1) | ECSP10010696A (es) |
ES (1) | ES2398423T3 (es) |
HK (1) | HK1155160A1 (es) |
IL (1) | IL210074A (es) |
MX (1) | MX2010014230A (es) |
MY (1) | MY172107A (es) |
NI (1) | NI201000225A (es) |
PE (1) | PE20110147A1 (es) |
SV (1) | SV2010003770A (es) |
TW (1) | TWI441821B (es) |
UY (1) | UY31917A (es) |
WO (1) | WO2009153597A2 (es) |
ZA (1) | ZA201101861B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009215375A1 (en) * | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
CN106008559B (zh) * | 2015-03-25 | 2020-10-16 | 中国科学院上海药物研究所 | 取代吡啶并嘧啶类化合物的合成工艺 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
EP3813946B1 (en) | 2018-06-15 | 2024-05-22 | Janssen Pharmaceutica NV | Rapamycin analogs and uses thereof |
BR112022010754A2 (pt) | 2019-12-05 | 2022-08-23 | Anakuria Therapeutics Inc | Análogos de rapamicina e usos dos mesmos |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560685A (en) * | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
DE3445298A1 (de) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
DE50012459D1 (de) | 1999-09-07 | 2006-05-11 | Syngenta Participations Ag | Neue Herbizide |
EP1277738B1 (en) | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
ES2518316T3 (es) | 2002-12-06 | 2014-11-05 | Debiopharm International Sa | Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia |
AU2004236239A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
GB0428475D0 (en) | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
US8232278B2 (en) | 2005-06-24 | 2012-07-31 | Gilead Sciences, Inc. | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C |
US20070128658A1 (en) * | 2005-11-14 | 2007-06-07 | Blackwell Helen E | Fluorescent dyes, methods and uses thereof |
CA2628920C (en) | 2005-11-22 | 2015-12-29 | Kudos Pharmaceuticals Limited | Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
RU2445312C2 (ru) * | 2006-08-23 | 2012-03-20 | Кудос Фармасьютиклз Лимитед | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR |
MX2010004074A (es) * | 2007-10-15 | 2010-07-02 | Astrazeneca Ab | Combinacion 059. |
-
2009
- 2009-06-18 CA CA2728183A patent/CA2728183C/en active Active
- 2009-06-18 MY MYPI2010006040A patent/MY172107A/en unknown
- 2009-06-18 MX MX2010014230A patent/MX2010014230A/es active IP Right Grant
- 2009-06-18 EA EA201100063A patent/EA019092B1/ru not_active IP Right Cessation
- 2009-06-18 EP EP09766158A patent/EP2303875B1/en active Active
- 2009-06-18 BR BRPI0914912A patent/BRPI0914912A2/pt not_active Application Discontinuation
- 2009-06-18 ES ES09766158T patent/ES2398423T3/es active Active
- 2009-06-18 CN CN2009801303297A patent/CN102137860B/zh active Active
- 2009-06-18 JP JP2011514132A patent/JP5607614B2/ja active Active
- 2009-06-18 US US12/487,294 patent/US8198441B2/en active Active
- 2009-06-18 KR KR1020117001287A patent/KR101668497B1/ko active IP Right Grant
- 2009-06-18 UY UY0001031917A patent/UY31917A/es not_active Application Discontinuation
- 2009-06-18 TW TW098120503A patent/TWI441821B/zh not_active IP Right Cessation
- 2009-06-18 AU AU2009261688A patent/AU2009261688B2/en not_active Ceased
- 2009-06-18 WO PCT/GB2009/050695 patent/WO2009153597A2/en active Application Filing
- 2009-06-18 PE PE2010001171A patent/PE20110147A1/es not_active Application Discontinuation
- 2009-06-19 AR ARP090102264A patent/AR072263A1/es unknown
-
2010
- 2010-12-16 IL IL210074A patent/IL210074A/en active IP Right Grant
- 2010-12-20 DO DO2010000391A patent/DOP2010000391A/es unknown
- 2010-12-20 NI NI201000225A patent/NI201000225A/es unknown
- 2010-12-20 SV SV2010003770A patent/SV2010003770A/es not_active Application Discontinuation
- 2010-12-20 CR CR11859A patent/CR11859A/es not_active Application Discontinuation
- 2010-12-20 CL CL2010001488A patent/CL2010001488A1/es unknown
- 2010-12-20 EC EC2010010696A patent/ECSP10010696A/es unknown
-
2011
- 2011-01-19 CO CO11005447A patent/CO6351729A2/es not_active Application Discontinuation
- 2011-03-10 ZA ZA2011/01861A patent/ZA201101861B/en unknown
- 2011-09-05 HK HK11109366.4A patent/HK1155160A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010696A (es) | Composiciones con y procedimientos para pirido[2,3-d]pirimidinas sustituidas con metilmorfolina | |
AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
BRPI1009652A2 (pt) | tecidos anticrobianos compreendendo peróxido | |
TW200714589A (en) | Phenylacetamides suitable as protein kinase inhibitors | |
AR094070A1 (es) | Haluro de zinc aminoacidos / trimetilglicina | |
JO2885B1 (en) | Protein kinase inhibitors | |
AR070357A1 (es) | Producto para cuidado oral y metodos de uso y manufactura del mismo | |
AR084285A1 (es) | Composiciones inmunogenicas | |
BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
HK1133257A1 (es) | ||
BRPI0515577A (pt) | compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação | |
CO6300927A2 (es) | Sales de arginina y un cation, productos de cuidado oral y personal que los contienen y metodos para preparar dichas sales y productos | |
MY159171A (en) | Hair dyeing agent, hair dyeing product combination, and its use method | |
EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
AR077422A1 (es) | Sales de inhibidores de plk | |
GEP20166481B (en) | (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
CR10989A (es) | Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas | |
UY37987A (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3- metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico. | |
UY30788A1 (es) | Compuestos quimicos | |
EA201100502A1 (ru) | Гликозидные производные и их применения | |
CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
UY38971A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |